Adelene Q. Perkins
BRUKERAbout Adelene Q. Perkins
Adelene Q. Perkins (age 65) has served on Bruker’s Board since 2017. She was CEO (2010–2023) and Chair (2012–2023) of Infinity Pharmaceuticals, and previously held senior roles at TransForm Pharmaceuticals, Genetics Institute (now Pfizer), and Bain & Company; she holds an MBA from Harvard Business School and a BS in Chemical Engineering from Villanova University .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Infinity Pharmaceuticals, Inc. | Chief Executive Officer; Chair of Board | CEO 2010–2023; Chair 2012–2023 | Led public clinical-stage biopharma; board leadership |
| TransForm Pharmaceuticals, Inc. | VP, Business & Corporate Development | Prior to acquisition by J&J (2000s) | Corporate strategy, BD |
| Genetics Institute (Pfizer unit) | Various roles; GM of DiscoverEase; CEO of MetaMorphix JV | 1992–1999 | Operational leadership in pharma tools JV with Johns Hopkins |
| Bain & Company | Consultant | 1985–1992 | Strategy consulting |
External Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| Massachusetts General Hospital | Board of Directors | Current | Finance & Real Estate, Naming, Research & Education Committees |
| Mass General Brigham | Audit & Compliance Committee | Current | System-level audit/compliance oversight |
| Project Hope (social service agency) | Board; Chair, Nominating & Governance | Current | Governance leadership |
| Archdiocese of Boston Catholic Community Fund | Board | Current | Philanthropic oversight |
Board Governance
- Committee assignments: Audit Committee member through 2024; Audit Committee met 8 times in 2024; after the 2025 Annual Meeting, Perkins transitions to the Nominating & Governance Committee (N&G). Audit (2024 members: Ornell [Chair], Perkins, Rosenthal). Post-2025 Audit members: Francis, Ornell, Rosenthal; Post-2025 N&G members: Anderson, Linton, Packer [Chair], Perkins .
- Independence: The Board determined all directors other than the CEO are independent under Nasdaq rules; no relationships impairing independence were identified for Perkins .
- Attendance and engagement: In 2024, every director attended at least 92% of Board and committee meetings; the Board holds executive sessions at each regularly scheduled meeting .
- Board leadership context: Combined Chair/CEO; lead director responsibilities handled by William Linton (succeeded by Richard Packer at the 2025 Annual Meeting). Relevance for Perkins: participation within a strong independent committee structure .
Fixed Compensation
| Component | 2024 Amount | Notes |
|---|---|---|
| Annual Board cash retainer | $72,500 | Non-employee director cash retainer |
| Audit Committee membership fee | $18,000 | Membership (not Chair) |
| Committee Chair fees | $0 | Perkins did not chair a committee in 2024 |
| Lead Director fee | $0 | Not applicable |
| Total cash paid (Perkins) | $90,500 | Sum of retainer + committee membership |
| 2024 Director Compensation (Perkins) | Amount |
|---|---|
| Fees Earned or Paid in Cash | $90,500 |
| Equity Awards (grant-date fair value) | $165,035 |
| Total | $255,535 |
Performance Compensation
- Annual equity structure: Non-employee directors receive annual RSUs valued at $165,035 that vest in full on the first anniversary of grant; on Jan 5, 2024, each director received 2,377 RSUs, vesting Jan 5, 2025. These are time-based awards; no performance metrics are attached .
| Equity Award Detail (Perkins) | Grant Date | RSUs | Grant-date Fair Value | Vesting |
|---|---|---|---|---|
| Annual RSU | Jan 5, 2024 | 2,377 | $165,035 | 100% on Jan 5, 2025 |
- Clawback/recoupment: Company-wide clawback applies to incentive-based comp for executive officers; the 2026 Plan also permits clawback of awards upon certain breaches or “Cause” (plan-wide, including non-employee directors), and prohibits hedging/pledging by directors .
Other Directorships & Interlocks
- Current public company directorships: None disclosed besides Bruker .
- Notable interlocks in Bruker ecosystem (awareness): Transactions with Asahi Kasei (director Richard Packer executive there) and with entities related to the CEO’s family, reviewed under RPT Policy; no disclosed transactions involving Perkins or her affiliated entities .
- RPT policy and review: CFO and Audit Committee oversee related-person transactions; thresholds and processes detailed; no impairment of independence found for independent directors .
Expertise & Qualifications
- Education: MBA, Harvard Business School; BS Chemical Engineering, Villanova University .
- Sector expertise: >35 years in pharma/life sciences, corporate strategy, BD; Audit Committee membership indicates financial literacy (Audit Chair designated expert is Ornell) .
- Nonprofit governance: Active roles across MGH/Mass General Brigham; chairing Nominating & Governance at Project Hope (governance skillset) .
Equity Ownership
| Holder | Shares Beneficially Owned | % of Class | Notes |
|---|---|---|---|
| Adelene Q. Perkins (as of Apr 1, 2025) | 21,326 | <1% | Beneficial ownership table |
| Adelene Q. Perkins (as of Apr 1, 2024) | 18,949 | <1% | Prior year reference |
| Equity Instruments (as of Dec 31, 2024) | Quantity |
|---|---|
| Unvested RSUs | 2,377 |
| Vested options | — (none) |
- Ownership guidelines: Directors must hold 5x annual cash retainer; unvested RSUs count toward compliance; all directors met guidelines, and must retain 50% of shares delivered until compliant .
- Hedging/pledging: Directors prohibited from hedging and pledging Bruker securities (no exceptions disclosed for Perkins) .
Governance Assessment
- Committee effectiveness: Perkins’ Audit Committee service in 2024 and move to N&G in 2025 align with her operational/strategy background and broaden governance oversight. Transition off Audit reduces direct financial oversight but strengthens Board governance processes through N&G participation .
- Independence and attendance: Independent with strong attendance (≥92%); executive sessions held each meeting support independent oversight .
- Alignment and incentives: Director pay is modest cash plus time-based RSUs; no performance metrics on director equity, but ownership guidelines and retention requirements support long-term alignment. 2024 equity grant (2,377 RSUs, $165,035) and cash ($90,500) are consistent with peers and roles .
- Investor confidence signals: Strong shareholder support for Perkins’ 2024 re-election (For 122,089,408; Withheld 2,901,967). Company-level Say-on-Pay support has been high (2024 For 119,998,889; Against 4,800,924; and 2025 For 108,807,969; Against 6,023,904), indicating favorable investor sentiment toward governance and compensation frameworks .
- Conflicts/related-party exposure: No related-party transactions disclosed involving Perkins; RPT processes are robust; overall independence affirmed for non-CEO directors .
- RED FLAGS: None specific to Perkins identified. Company-wide: CEO family-related leases and select customer/supplier transactions reviewed under policy; not tied to Perkins .
Net: Perkins brings deep industry and governance expertise, maintains independence and attendance, and follows strong ownership alignment. Committee rotation to N&G enhances board governance quality without introducing conflicts.